Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14627615 | 0.84 | DPP4 (0.45) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL13077266 | 0.84 | DPP4 (0.45) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL3469048 | 0.84 | DPP4 (0.45) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2738406 | 0.81 | KDM4E (0.43) | DPP4F2ADRA2AADRA2C | |
| SCHEMBL21554360 | 0.80 | DPP4 (0.41) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL14479727 | 0.78 | SIGMAR1 (0.34) | SIGMAR1 | |
| SCHEMBL21165081 | 0.78 | EPHX1 (0.38) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL20311848 | 0.77 | AOC3 (0.33) | CYP3A4CYP1A2TSHRHSD17B10 | |
| SCHEMBL18726338 | 0.76 | CYP2D6 (0.35) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL5948196 | 0.75 | HRH1 (0.43) | CYP3A4CYP1A2CYP2D6TSHRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | CYP3A4 2805/4885CYP1A2 1369/4885CYP2D6 1573/4885 |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | CYP3A4 115/4885CYP1A2 28/4885CYP2D6 141/4885 |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | TYR, MC1R, F12 | CYP3A4 106/4885CYP1A2 28/4885CYP2D6 116/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | CYP3A4 104/4885CYP1A2 27/4885CYP2D6 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.